Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy
U Ali, S Vungarala, V Tiriveedhi - Genes, 2024 - mdpi.com
Simple Summary Cancer is the second most common cause of death in the USA. Genomic
instability is one of the well-established hallmarks of cancer. The homologous recombination …
instability is one of the well-established hallmarks of cancer. The homologous recombination …
[HTML][HTML] Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis
N Wu, X Zhang, C Fang, M Zhu, Z Wang, L Jian, W Tan… - Research, 2024 - spj.science.org
Poly (adenosine 5′-diphosphate-ribose) polymerase inhibitors (PARPi) are increasingly
important in the treatment of ovarian cancer. However, more than 40% of BRCA1/2-deficient …
important in the treatment of ovarian cancer. However, more than 40% of BRCA1/2-deficient …
[HTML][HTML] Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)
L Incorvaia, G Badalamenti, G Novo, S Gori, L Cortesi… - ESMO open, 2024 - Elsevier
Background The BRCA proteins play a key role in the homologous recombination (HR)
pathway. Beyond BRCA1/2, other genes are involved in the HR repair (HRR). Due to the …
pathway. Beyond BRCA1/2, other genes are involved in the HR repair (HRR). Due to the …